New mouse models give a boost to the development of cancer immunotherapies

A new cancer treatment called CD40 inhibitor has yielded disappointing results when tested in clinical trials, failing to mobilize patients’ immune system against tumors the way it was expected to. But a recent study offers clues about how this experimental drug might be optimized to fulfill its potential. More »
Source: The Rockefeller University Newswire - Category: Biomedical Science Authors: Tags: Science News cancer CD40 immunology immunotherapy Jeffrey Ravetch Laboratory of Molecular Genetics and Immunology Source Type: news